UroGen Pharma Ltd. Ordinary Shares (URGN) Financials
Key financial figures for UroGen Pharma Ltd. Ordinary Shares (Q2 2026).
UroGen Pharma Ltd. reported revenue of $72.5 million for Q2 FY2026, up 199.2% from the same period a year earlier. The company posted a net loss of $14.4 million, or -$0.28 per share. Operating margin came to 0.15%, against -171.17% a year earlier. Free cash flow for the period was -$33.1 million. Across the last 5 reported quarters, quarterly revenue has risen from $24.2 million in Q2 FY2025 to $72.5 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for UroGen Pharma Ltd. are on the SentiSense financials page.
- Revenue
- $72M
- Net Income
- -$14M
- EPS
- $-0.28
- Total Assets
- $253M
- Operating Cash Flow
- -$33M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $72M | -$14M | -$0.28 | 0.15% | -$33M |
| Q1 FY2026 | $51M | -$24M | -$0.47 | -39.76% | -$45M |
| Q4 FY2025 | $38M | -$26M | -$0.54 | -50.52% | -$38M |
| Q3 FY2025 | $27M | -$33M | -$0.69 | -99.65% | -$42M |
| Q2 FY2025 | $24M | -$50M | -$1.05 | -171.17% | -$40M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $110M | -$153M | -$3.19 | -113.73% | -$163M |
| FY2024 | $90M | -$127M | -$2.96 | -107.06% | -$97M |
| FY2023 | $83M | -$102M | -$3.55 | -79.23% | -$77M |
Frequently asked questions
What was UroGen Pharma Ltd.'s revenue last quarter?
UroGen Pharma Ltd. reported revenue of $72.5 million for Q2 FY2026, up 199.2% from the same period a year earlier.
Is UroGen Pharma Ltd. profitable?
Not in its most recent reported period. UroGen Pharma Ltd. reported a net loss of $14.4 million for Q2 FY2026, a net margin of -19.81% on revenue.
How has UroGen Pharma Ltd.'s margin trended?
Operating margin was 0.15% in Q2 FY2026, compared with -171.17% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did UroGen Pharma Ltd. generate?
UroGen Pharma Ltd. generated free cash flow of -$33.1 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for UroGen Pharma Ltd. Ordinary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.